Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-223 in advanced solid tumors, NHL, or multiple myeloma
NCT01177397Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2010
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of onatasertib in multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), glioblastoma multiforme (GBM), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), sponsored by Celgene Corporation. Started Jul 2010; status: completed.
02
Drugs
onatasertib
03
Conditions
multiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)glioblastoma multiforme (GBM)hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01177397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01177397.